Integra LifeSciences Holdings Corporation
General ticker "IART" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $1.3B (TTM average)
Integra LifeSciences Holdings Corporation does not follow the US Stock Market performance with the rate: -1.0%.
Estimated limits based on current volatility of 1.9%: low 13.24$, high 13.76$
Factors to consider:
- Total employees count: 4396 (+11.4%) as of 2024
- US accounted for 74.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Acquisition/divestiture risks, Regulatory and compliance, Labor/talent shortage/retention, Cybersecurity threats
- Current price 14.5% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [15.88$, 29.13$]
- 2025-12-31 to 2026-12-31 estimated range: [16.15$, 29.28$]
Financial Metrics affecting the IART estimates:
- Positive: with PPE of 8.7 at the end of fiscal year the price was neutral
- Positive: -3.60 < Operating profit margin, % of 1.76
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 7.56
- Negative: Industry earnings per price (median), % of -3.67 <= 0
- Positive: 18.93 < Shareholder equity ratio, % of 38.27 <= 41.86
- Positive: Industry inventory ratio change (median), % of -1.44 <= -0.15
- Negative: 0 < Inventory ratio change, % of 0.81
Short-term IART quotes
Long-term IART plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,557.67MM | $1,541.57MM | $1,610.53MM |
| Operating Expenses | $1,318.75MM | $1,430.05MM | $1,582.12MM |
| Operating Income | $238.92MM | $111.53MM | $28.41MM |
| Non-Operating Income | $-25.03MM | $-30.46MM | $-46.65MM |
| Interest Expense | $49.59MM | $51.38MM | $70.63MM |
| R&D Expense | $101.19MM | $104.19MM | $115.38MM |
| Income(Loss) | $213.89MM | $81.07MM | $-18.24MM |
| Taxes | $33.34MM | $13.33MM | $-11.29MM |
| Profit(Loss)* | $180.55MM | $67.74MM | $-6.94MM |
| Stockholders Equity | $1,804.40MM | $1,587.88MM | $1,545.28MM |
| Inventory | $324.58MM | $389.61MM | $429.09MM |
| Assets | $3,889.76MM | $3,781.99MM | $4,037.42MM |
| Operating Cash Flow | $264.47MM | $139.96MM | $129.38MM |
| Capital expenditure | $47.09MM | $66.86MM | $104.42MM |
| Investing Cash Flow | $-58.58MM | $-94.18MM | $-390.81MM |
| Financing Cash Flow | $-251.95MM | $-229.93MM | $237.86MM |
| Earnings Per Share** | $2.18 | $0.87 | $-0.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.